The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BMS "doesn't see" Amgen's established psoriasis drug Otezla hurting Sotyku's uptake, chief commercial officer Chris Boerner said Thursday. (Bristol Myers Squibb ) By winning three first-in-class drug ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with active psoriatic arthritis (PsA). The decision adds a second major ...
BMY expands Sotyktu into PsA, strengthening its immunology portfolio and growth strategy. Sotyktu faces rivalry from Amgen's Otezla and Novartis' Cosentyx in key markets. Legacy drugs face generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results